# BNTX catalysts: BioNTech SE PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/bntx/catalysts

> BioNTech SE (BNTX) has 24 upcoming catalysts. The next is the BNT162B2 topline data readout, Apr to Jul 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | BioNTech SE |
| Ticker | BNTX (Nasdaq) |
| SEC CIK | 1776985 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/bntx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2024 | [KANJINTI® (trastuzumab) trial start](https://sec-api.dev/pdufa/trastuzumab) | BNTX | HER2-expressing advanced solid tumors | completed | "In January 2024, the partners initiated a global Phase 3 DYNASTY-Breast02 trial program for trastuzumab pamirtecan in HR-positive, HER2-low metastatic breast cancer (DYNASTY-Breast02, NCT06018337) following positive Phase 1/2 safety and efficacy data in patients with HER2-expressing advanced solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000055/a99120250905_bnt323xdb-130.htm)) |
| Jun 2024 | [DB-1305 trial start](https://sec-api.dev/pdufa/db-1305) | BNTX |  | completed | "In June 2024, the evaluation of BNT327/PM8002 in combination with BNT325/DB-1305, a Trophoblast Cell-Surface Antigen 2 ("TROP2")-targeted ADC candidate developed by BioNTech in collaboration with Duality Biologics (Suzhou) Co., Ltd. ("DualityBio"), was initiated as part of an ongoing Phase 1/2 clinical trial (NCT05438329)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698524000094/a99_1biontechtoacquirebiot.htm)) |
| Jul 2024 | [BioNTech SE topline data readout](https://sec-api.dev/companies/bntx/catalysts) | BNTX |  | completed, positive | "Data published (Lopez et al., Nature Medicine 2025) Enrollment completed Positive topline data announced July 2024 Data presented from Ph 1 at multiple conferences incl. SITC 2021 and published (Sahin et al., Nature 2020)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000002/a99_2biontechjpmx2025.htm)) |
| Dec 2024 | [Pumitamig trial start](https://sec-api.dev/pdufa/pumitamig) | BNTX |  | completed | "•In December 2024, BioNTech initiated a global randomized Phase 3 clinical trial (NCT06712355) evaluating BNT327 plus chemotherapy compared to atezolizumab plus chemotherapy in first-line extensive-stage small cell lung cancer ("ES-SCLC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000011/ex99250310_bntxxprxq42024x.htm)) |
| Dec 2024 | [Pumitamig interim data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX |  | completed, negative | "•In December 2024, at the San Antonio Breast Cancer Symposium ("SABCS"), interim data were presented from the Phase 1/2 clinical trial (NCT05918133) evaluating BNT327 in combination with chemotherapy in a cohort of patients with locally advanced, previously untreated triple-negative breast cancer ("TNBC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000011/ex99250310_bntxxprxq42024x.htm)) |
| 2025 | [BNT323 trial start](https://sec-api.dev/pdufa/bnt323) | BNTX |  | scheduled | "•Plan to initiate a global Phase 3 confirmatory clinical trial (NCT06340568) evaluating BNT323/DB-1303 in advanced endometrial cancer in 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000002/a99_1bntxjpmorganhealthcar.htm)) |
| Feb 2025 | [Autogene trial start](https://sec-api.dev/pdufa/autogene) | BNTX | pancreatic ductal adenocarcinoma | completed | "In February 2025, a manuscript denoting follow up data from an investigator-initiated Phase 1 clinical trial (NCT04161755, Rojas et al., 2023) evaluating autogene cevumeran in combination with atezolizumab in patients with pancreatic ductal adenocarcinoma ("PDAC") in an adjuvant treatment setting was published in Nature (Sethna et al., 2025)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000011/ex99250310_bntxxprxq42024x.htm)) |
| Jul 2025 | [BNT324 trial start](https://sec-api.dev/pdufa/bnt324) | BNTX | advanced solid tumors | completed | "-In July 2025, the first patient was dosed in a Phase 2 clinical trial (NCT06953089) evaluating BNT324/DB-1311 in combination with pumitamig or with TROP2 ADC candidate BNT325/DB-1305 in patients with advanced solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm)) |
| Aug 2025 | [GEN1059 trial start](https://sec-api.dev/pdufa/bnt314) | BNTX | advanced colorectal cancer | completed | "-In August 2025, the first patient was dosed in a Phase 1/2 clinical trial (NCT07079631) to evaluate BNT314/GEN1059 in combination with pumitamig and chemotherapy in patients with advanced colorectal cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm)) |
| August 27, 2025 | [COMIRNATY (comirnaty) label expansion decision](https://sec-api.dev/pdufa/comirnaty) | BNTX |  | completed, approved | "NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.2" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000053/a991250827_covid-19lp815fd.htm)) |
| Sep 2025 | [BioNTech SE topline data readout](https://sec-api.dev/companies/bntx/catalysts) | BNTX |  | completed, positive | "In September 2025, we announced positive topline results from the Phase 3 trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm)) |
| Sep 2025 | [KANJINTI® (trastuzumab) trial start](https://sec-api.dev/pdufa/trastuzumab) | BNTX | advanced endometrial cancer | completed | "-In September 2025, the first patient was dosed in a Phase 3 trial (NCT06340568) to evaluate trastuzumab pamirtecan compared to investigator's choice of chemotherapy in patients with advanced endometrial cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm)) |
| September 5, 2025 | [KANJINTI® (trastuzumab) interim data readout](https://sec-api.dev/pdufa/trastuzumab) | BNTX | HER2-positive unresectable or metastatic breast cancer | completed, met | "MAINZ, Germany and SHANGHAI, China, September 05, 2025 - BioNTech SE (Nasdaq: BNTX, "BioNTech") and Duality Biologics (Suzhou) Co., Ltd. ("DualityBio") today announced that the pivotal Phase 3 trial (NCT06265428) which DualityBio is conducting in China to evaluate trastuzumab pamirtecan (BNT323/DB-1303) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and a taxane-based chemotherapy met its primary endpoint of progression free survival at a pre-specified interim analysis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000055/a99120250905_bnt323xdb-130.htm)) |
| Oct 2025 | [BNT326 trial start](https://sec-api.dev/pdufa/bnt326) | BNTX |  | completed | "-In October 2025, the first patient was dosed in a Phase 1/2 clinical trial (NCT07111520) to evaluate BNT326/YL202 in combination with pumitamig in advanced NSCLC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm)) |
| December 9, 2025 | [Pumitamig interim data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | locally advanced/metastatic triple-negative breast cancer | completed, negative | "MAINZ, Germany, and PRINCETON, USA, December 9, 2025 - BioNTech SE (Nasdaq: BNTX, "BioNTech") and Bristol Myers Squibb Company (NYSE: BMY, "BMS") today announced the first interim data from a global randomized Phase 2 trial (NCT06449222) evaluating pumitamig (BNT327/BMS986545), an investigational bispecific antibody targeting PD-L1 and VEGF-A, plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer ("TNBC") irrespective of PD-L1 expression levels." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000071/a991251209_bntxbmsxprxpumi.htm)) |
| 2026 | [Elfetabart trial start](https://sec-api.dev/pdufa/elfetabart) | BNTX |  | scheduled | "•Multiple milestones achieved in 2026, including initiation of six pivotal trials - five for pumitamig and one for B7-H3-targeting ADC candidate elfetabart drozuntecan; upcoming 2026 catalysts include three late-stage readouts expected across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapies" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000054/a991bntx_q22026pressreleas.htm)) |
| 2026 | [Gotistobart interim data readout](https://sec-api.dev/pdufa/gotistobart) | BNTX |  | scheduled | "Median OS was 18.5 months with gotistobart1 vs 10.0 months with docetaxel2 Gotistobart continues to show potential as chemotherapy-free treatment option in a hard-to-treat lung cancer setting Gotistobart reduced the risk of death by 44% vs. chemotherapy 25.4 month follow-up data from non-pivotal part of Phase 3 presented at WCLC 2026 Observed overall safety profile aligns with its previously established safety findings Pivotal Phase 3 in sqNSCLC ongoing with gotistobart monotherapy as chemo-free 2L+ treatment option First interim analysis of pivotal Phase 3 expected in 2026 Development Status Clinical Evidence" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000080/a992bntx3q2026presentati.htm)) |
| 2026 | [KANJINTI® (trastuzumab) NDA/BLA submission](https://sec-api.dev/pdufa/trastuzumab) | BNTX |  | scheduled | "•While BioNTech and DualityBio plan to file a biologics license application ("BLA") in 2026, the companies will determine the optimal regulatory path for trastuzumab pamirtecan based on the totality of clinical data in endometrial cancer and breast cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000054/a991bntx_q22026pressreleas.htm)) |
| 2026 | [BNT113 interim data readout](https://sec-api.dev/pdufa/bnt113) | BNTX | unresectable recurrent or metastatic, PD-L1+, HPV16+ HNSCC | scheduled | "•Based on current event accrual projections, data are expected in 2026 from the first interim analysis of the Phase 3 part of the ongoing Phase 2/3 clinical trial (AHEAD-MERIT; NCT04534205) evaluating BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent or metastatic, PD-L1+, HPV16+ HNSCC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000016/a991bntxq4_pr.htm)) |
| May 1, 2026 | [Bnt162b2 (2025/2026 recommended sars-cov-2 strain) primary completion](https://sec-api.dev/pdufa/bnt162b2-2025-2026-recommended-sars-cov-2-strain) | BNTX | COVID-19; SARS-COV-2 Infection | completed | "NCT07069309 (A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07069309)) |
| Jun 2026 | [BioNTech SE NDA/BLA submission](https://sec-api.dev/companies/bntx/catalysts) | BNTX |  | completed | "In June 2026, we submitted a marketing authorization application to the EMA and a supplemental Biologics License Application to FDA for our Omicron XFG variant-adapted monovalent COVID-19 vaccine." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm)) |
| July 10, 2026 | [Bivalent bnt162b2 (original/omicron ba.4/ba.5) 3 microgram dose primary completion](https://sec-api.dev/pdufa/bivalent-bnt162b2-original-omicron-ba-4-ba-5-3-microgram-dose) | BNTX | SARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19 | completed | "NCT05543616 (A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-10 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05543616)) |
| July 24, 2026 | [Bnt162b2 (2025/2026 formulation) primary completion](https://sec-api.dev/pdufa/bnt162b2-2025-2026-formulation) | BNTX | COVID-19; SARS-COV-2 Infection | completed | "NCT07222384 (A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-24 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222384)) |
| Aug 2026 | [BioNTech SE label expansion decision](https://sec-api.dev/companies/bntx/catalysts) | BNTX |  | completed, approved | "•In August 2026, the United States Food and Drug Administration ("FDA") approved the supplemental Biologics License Application ("sBLA") for BioNTech and Pfizer's monovalent XFG-adapted COVID-19 vaccine for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000080/a99120261103_bntxq32026pre.htm)) |
| August 27, 2026 | [COMIRNATY (comirnaty) label expansion decision](https://sec-api.dev/pdufa/comirnaty) | BNTX |  | completed, approved | "NEW YORK and MAINZ, GERMANY, August 27, 2026 — Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies' 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.1" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000059/a991bntx_covid-19xfgvarian.htm)) |
| September 22, 2026 | [Bnt162b2 vaccine primary completion](https://sec-api.dev/pdufa/bnt162b2-vaccine) | BNTX | COVID-19; SARS-COV-2 Infection | completed | "NCT07300839 (A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07300839)) |
| Sep to Dec 2026 | [Bnt162b2 vaccine topline data readout](https://sec-api.dev/pdufa/bnt162b2-vaccine) | BNTX | COVID-19; SARS-COV-2 Infection | scheduled | "NCT07300839 (A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07300839)) |
| Q4 2026 | [BioNTech SE interim data readout](https://sec-api.dev/companies/bntx/catalysts) | BNTX |  | scheduled | "-Based on current event accrual projections, we expect interim data from this trial in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm)) |
| November 2026 | [Ro7198457 intravenous (iv) primary completion](https://sec-api.dev/pdufa/ro7198457-intravenous-iv) | BNTX | Colorectal Cancer Stage II; Colorectal Cancer Stage III | scheduled | "NCT04486378 (A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04486378)) |
| Nov 2026 to Feb 2027 | [Ro7198457 intravenous (iv) topline data readout](https://sec-api.dev/pdufa/ro7198457-intravenous-iv) | BNTX | Colorectal Cancer Stage II; Colorectal Cancer Stage III | scheduled | "NCT04486378 (A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04486378)) |
| Apr to Jul 2027 | [BNT162B2 topline data readout](https://sec-api.dev/pdufa/bnt162b2) | BNTX | COVID-19 Vaccines | scheduled | "NCT07798648 (A Study of COVID-19 Vaccine(s) in Children and Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-21 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07798648)) |
| April 2027 | [BNT162B2 primary completion](https://sec-api.dev/pdufa/bnt162b2) | BNTX | COVID-19 Vaccines | scheduled | "NCT07798648 (A Study of COVID-19 Vaccine(s) in Children and Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-21 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07798648)) |
| June 2027 | [Bnt327 dose level 1 (dl1) primary completion](https://sec-api.dev/pdufa/bnt327-dose-level-1-dl1) | BNTX | Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer | scheduled | "NCT06449209 (Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06449209)) |
| Jun to Sep 2027 | [Bnt327 dose level 1 (dl1) topline data readout](https://sec-api.dev/pdufa/bnt327-dose-level-1-dl1) | BNTX | Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer | scheduled | "NCT06449209 (Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06449209)) |
| June 2027 | [BNT166A primary completion](https://sec-api.dev/pdufa/bnt166a) | BNTX | Mpox (Monkeypox); Smallpox; Orthopoxvirus Infection | scheduled | "NCT07379580 (A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07379580)) |
| Jun to Sep 2027 | [BNT166A topline data readout](https://sec-api.dev/pdufa/bnt166a) | BNTX | Mpox (Monkeypox); Smallpox; Orthopoxvirus Infection | scheduled | "NCT07379580 (A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07379580)) |
| December 2027 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BNTX | Pancreatic Ductal Adenocarcinoma (PDAC) | scheduled | "NCT07255404 (A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07255404)) |
| Dec 2027 to Mar 2028 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | Pancreatic Ductal Adenocarcinoma (PDAC) | scheduled | "NCT07255404 (A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07255404)) |
| January 2028 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BNTX | Recurrent Glioblastoma | scheduled | "NCT07297212 (A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07297212)) |
| Jan to Apr 2028 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | Recurrent Glioblastoma | scheduled | "NCT07297212 (A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07297212)) |
| March 2028 | [Bnt323/db-1303 primary completion](https://sec-api.dev/pdufa/bnt323-db-1303) | BNTX | Endometrial Cancer | scheduled | "NCT06340568 (A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340568)) |
| Mar to Jun 2028 | [Bnt323/db-1303 topline data readout](https://sec-api.dev/pdufa/bnt323-db-1303) | BNTX | Endometrial Cancer | scheduled | "NCT06340568 (A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340568)) |
| August 2028 | [Bnt327 dose level 1 (dl1) primary completion](https://sec-api.dev/pdufa/bnt327-dose-level-1-dl1) | BNTX |  | scheduled | "NCT06449222 (Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06449222)) |
| Aug to Nov 2028 | [Bnt327 dose level 1 (dl1) topline data readout](https://sec-api.dev/pdufa/bnt327-dose-level-1-dl1) | BNTX |  | scheduled | "NCT06449222 (Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06449222)) |
| October 2028 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BNTX | Non-small Cell Lung Cancer | scheduled | "NCT06841055 (Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06841055)) |
| Oct 2028 to Jan 2029 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | Non-small Cell Lung Cancer | scheduled | "NCT06841055 (Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06841055)) |
| January 2029 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BNTX | Non-small Cell Lung Cancer | scheduled | "NCT06712316 (Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712316)) |
| Jan to Apr 2029 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | Non-small Cell Lung Cancer | scheduled | "NCT06712316 (Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712316)) |
| April 2029 | [BNT113 primary completion](https://sec-api.dev/pdufa/bnt113) | BNTX |  | scheduled | "NCT04534205 (A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04534205)) |
| Apr to Jul 2029 | [BNT113 topline data readout](https://sec-api.dev/pdufa/bnt113) | BNTX |  | scheduled | "NCT04534205 (A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04534205)) |
| April 2029 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BNTX | Extensive-stage Small-cell Lung Cancer | scheduled | "NCT06712355 (Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712355)) |
| Apr to Jul 2029 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | Extensive-stage Small-cell Lung Cancer | scheduled | "NCT06712355 (Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712355)) |
| December 2029 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BNTX | Breast Neoplasms | scheduled | "NCT07173751 (ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07173751)) |
| Dec 2029 to Mar 2030 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | Breast Neoplasms | scheduled | "NCT07173751 (ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07173751)) |

## Drugs

- [Autogene](https://sec-api.dev/pdufa/autogene): pancreatic ductal adenocarcinoma
- [Bivalent bnt162b2 (original/omicron ba.4/ba.5) 3 microgram dose](https://sec-api.dev/pdufa/bivalent-bnt162b2-original-omicron-ba-4-ba-5-3-microgram-dose): SARS-CoV-2 Virus
- [BNT113](https://sec-api.dev/pdufa/bnt113): unresectable recurrent or metastatic, pd-l1+, hpv16+ hnscc, Unresectable Head and Neck Squamous Cell Carcinoma
- [BNT162B2](https://sec-api.dev/pdufa/bnt162b2): COVID-19 Vaccines
- [Bnt162b2 (2025/2026 formulation)](https://sec-api.dev/pdufa/bnt162b2-2025-2026-formulation): COVID-19
- [Bnt162b2 (2025/2026 recommended sars-cov-2 strain)](https://sec-api.dev/pdufa/bnt162b2-2025-2026-recommended-sars-cov-2-strain): COVID-19
- [Bnt162b2 vaccine](https://sec-api.dev/pdufa/bnt162b2-vaccine): COVID-19
- [BNT166A](https://sec-api.dev/pdufa/bnt166a): Mpox (Monkeypox)
- [GEN1059](https://sec-api.dev/pdufa/bnt314): advanced colorectal cancer
- [BNT323](https://sec-api.dev/pdufa/bnt323): 
- [Bnt323/db-1303](https://sec-api.dev/pdufa/bnt323-db-1303): Endometrial Cancer
- [BNT324](https://sec-api.dev/pdufa/bnt324): advanced solid tumors
- [BNT326](https://sec-api.dev/pdufa/bnt326): 
- [Bnt327 dose level 1 (dl1)](https://sec-api.dev/pdufa/bnt327-dose-level-1-dl1): Locally Advanced Breast Cancer, Extensive-stage Small-cell Lung Cancer
- [COMIRNATY (comirnaty)](https://sec-api.dev/pdufa/comirnaty): 
- [DB-1305](https://sec-api.dev/pdufa/db-1305): 
- [Elfetabart](https://sec-api.dev/pdufa/elfetabart): 
- [Gotistobart](https://sec-api.dev/pdufa/gotistobart): 
- [Ro7198457 intravenous (iv)](https://sec-api.dev/pdufa/ro7198457-intravenous-iv): Colorectal Cancer Stage II
- [KANJINTI® (trastuzumab)](https://sec-api.dev/pdufa/trastuzumab): advanced endometrial cancer, her2-positive unresectable or metastatic breast cancer, her2-expressing advanced solid tumors

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/bntx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BNTX catalysts: BioNTech SE PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/bntx/catalysts

```bibtex
@misc{secapidev_companies_bntx_catalysts_20261116,
  title        = {BNTX catalysts: BioNTech SE PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/bntx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_bntx_catalysts_20261116","title":"BNTX catalysts: BioNTech SE PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/bntx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
